-+ 0.00%
-+ 0.00%
-+ 0.00%

Belite Bio starts FDA rolling NDA submission for tinlarebant in Stargardt disease

PUBT·04/21/2026 20:00:23
Listen to the news
Belite Bio starts FDA rolling NDA submission for tinlarebant in Stargardt disease
  • Belite Bio initiated a rolling NDA submission to FDA for tinlarebant to treat Stargardt disease type 1.
  • Rolling filing proceeds under FDA Breakthrough Therapy Designation.
  • Completion of NDA submission targeted for Q2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211600PRIMZONEFULLFEED9694109) on April 21, 2026, and is solely responsible for the information contained therein.